← Back to Search

ABC123 Framework for Advanced Bladder Cancer

N/A
Recruiting
Led By Elizabeth Kessler
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age >65 years old, or >60 with at least one deficit on a geriatric screen
English speaking only for the pilot portion
Must not have
Have a diagnosis of a different advanced cancer that has required systemic therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new care planning framework called ABC123 for older patients with advanced cancer. It combines tools from elderly care, cancer treatment, and comfort care to create personalized plans. The goal is to ensure that the care aligns with what patients want and need.

Who is the study for?
This trial is for people over 60 with advanced, incurable cancer who are seeing an oncologist for the first time. They must be able to sign a consent form, follow study procedures for 6 months, and speak English. It's not open to those who've had systemic therapy for another advanced cancer or have conditions that could interfere with the study.
What is being tested?
The ABC123 framework is being tested in this pilot study. It integrates geriatric, oncology, and palliative medicine into care planning by an advanced practice provider alongside a medical oncologist. The goal is to see if it's feasible and matches patient-clinician goals.
What are the potential side effects?
Since this trial tests a care planning framework rather than medication, traditional side effects like you'd expect from drugs aren't applicable here. However, there may be emotional or psychological impacts from discussing advanced cancer care plans.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am over 65, or over 60 with a health issue found in a senior's health check.
Select...
I speak English.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been treated with medication for another advanced cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feasibility measured through recruitment
Feasibility measured through retention in follow up
Denture Retention

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Older patients with advanced cancerExperimental Treatment1 Intervention
Patients over 60 years old with advanced, incurable cancer.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common cancer treatments include chemotherapy, radiation therapy, and targeted therapy. Chemotherapy targets rapidly dividing cells, including cancer cells, but can also affect healthy cells, leading to side effects. Radiation therapy uses high-energy particles or waves to damage or destroy cancer cells by disrupting their DNA. Targeted therapy involves drugs that specifically target molecular markers or pathways essential for cancer cell survival and proliferation, minimizing damage to normal cells. Integrating these treatments with geriatric and palliative care principles, as in the ABC123 Framework, is crucial for older adults to tailor treatment to their overall health, manage side effects, and improve quality of life.
How to incorporate geriatric assessment in clinical decision-making for older patients with cancer. An implementation study.National consensus in China on diagnosis and treatment of patients with advanced breast cancer.

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,800 Previous Clinical Trials
2,821,862 Total Patients Enrolled
American Cancer Society, Inc.OTHER
228 Previous Clinical Trials
107,303 Total Patients Enrolled
Elizabeth KesslerPrincipal InvestigatorUniversity of Colorado, Denver

Media Library

ABC123 Framework Clinical Trial Eligibility Overview. Trial Name: NCT05408507 — N/A
Cancer Research Study Groups: Older patients with advanced cancer
Cancer Clinical Trial 2023: ABC123 Framework Highlights & Side Effects. Trial Name: NCT05408507 — N/A
ABC123 Framework 2023 Treatment Timeline for Medical Study. Trial Name: NCT05408507 — N/A
~20 spots leftby Dec 2025